Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rhein or rhein compound-arginine complex in preparation of medicines for treating diabetic vascular complications

A technology for treating drugs and arginine, which can be used in drug combinations, urinary system diseases, medical preparations with non-active ingredients, etc., and can solve problems such as low male sexual function

Inactive Publication Date: 2013-07-17
ZHEJIANG CHINESE MEDICAL UNIV MEDICAL PIECES
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0028] The above inventions have not yet involved the use of rhein or rhein compound compounds to treat diabetic complications, including the treatment of diabetic cardiomyopathy; diabetic macroangiopathy; male sexual dysfunction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhein or rhein compound-arginine complex in preparation of medicines for treating diabetic vascular complications
  • Application of rhein or rhein compound-arginine complex in preparation of medicines for treating diabetic vascular complications
  • Application of rhein or rhein compound-arginine complex in preparation of medicines for treating diabetic vascular complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1, the compound of rhein and arginine (macroarginic acid) treats diabetic cardiomyopathy.

[0094] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0095] Pharmacodynamic observation: It consists of macroscopic main pharmacodynamic indicators, expression of important bioactive molecules (mRNA, and protein) in diseased cells and other indicators.

[0096] Sarginic acid restored the above indicators to the normal...

Embodiment 2

[0098] Example 2, the treatment of diabetic macroangiopathy with sarginic acid. Basically the same as Example 1,

[0099] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0100] The vasodilation function and NO bioavailability were restored after 4 weeks of treatment with sarginic acid and aminoguanidine. At the same time, the molecular biological targets abnormally expressed in the blood vessel wall are basically restored t...

Embodiment 3

[0102] Example 3, the treatment of diabetic nephropathy with macrospermic acid.

[0103] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks. Treatment (mg / kg, intragastric administration): positive drug aminoguanidine 100, 3 dosage groups of spermatic acid: 50mg / kg, 100mg / kg, 200mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0104]The trace protein in 24h urine of rats with diabetic nephropathy increased significantly, and the creatinine and non-protein nitrogen in blood increased, suggesting: diabetic nephropathy. At the same time, the molecular biological indicators: the gene and protein expressi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a rhein-arginine complex in the preparation of medicines for treating diabetic nephropathies. The medicines for treating diabetic nephropathies are medicines for improving tiny amounts of proteinuria, creatinine and non-protein nitrogen. The medicines are novel medicines having a good safety, have better medicine effects than traditional treatment medicines and treatment methods, and allow the examples of a traditional Chinese medicinal super-molecule technology in the reconstruction of important effective components to be started and the researches and applications of the super-molecule technology in traditional Chinese medicines innovated medicines to be enlarged. The rhein-arginine complex is called rhein-arginine for short, is a new crystalline compound, and releases rhein and arginine after the rhein-arginine enters a body; and the dissolvability of rhein is changed, and the bioavailability is improved; the stability is good; a rhein parent compound is endowed with a new structural characteristic; and the rhein-arginine can inhibit a plurality of inflammatory factors comprising NFkappaB, TNFalpha, ROS, EGF and the like, can regulate the endothelin system and can improve endothelial cells.

Description

[0001] This application is a divisional application. [0002] The application number of the original application is: 201010115021X; the application date is: February 26, 2010; the title of the invention is: the application of rhein or a complex of rhein compounds and arginine in the preparation of drugs for treating diabetic complications. Except for the subject matter of the invention, the following descriptions are the original texts of the original descriptions. technical field [0003] The invention relates to the application of rhein or a complex of rhein compounds and arginine in the preparation of drugs for treating diabetic vascular complications. Drugs for the treatment of diabetic vascular complications refer to: drugs against endoplasmic reticulum stress in diseased organ lesion cells, and drugs that inhibit endothelin, ROS, and inflammatory substances. Background technique [0004] Diabetes and its complications are common and frequently-occurring diseases. The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61K47/48A61P3/10A61P13/12A61K47/54
Inventor 丛晓东戴德哉张云戴茵
Owner ZHEJIANG CHINESE MEDICAL UNIV MEDICAL PIECES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com